Difficulty: Medium
Average Score: 69%
Testbank
A patient states that PMS that is significantly disrupting her quality of life and that conservative management has failed to produce relief. What pharmacologic treatment may benefit this patient?
Correct answer
D
Rationale
D: A selective serotonin reuptake inhibitor (SSRI) may benefit this patient by alleviating the emotional and physical symptoms associated with premenstrual syndrome (PMS), particularly when conservative measures have been ineffective.
SSRIs are often prescribed for PMS due to their effectiveness in reducing mood-related symptoms such as irritability and depression, which can significantly disrupt quality of life. They also help with physical symptoms by influencing neurotransmitter levels, making them a suitable option for this patient.
A: An opioid analgesic is not appropriate for PMS management, as it primarily addresses pain and may lead to dependency without targeting the underlying hormonal or emotional issues associated with the condition.
B: A calcium channel blocker does not address the core symptoms of PMS and is typically used for cardiovascular conditions, making it unsuitable for this patient's hormonal-related symptoms and quality of life concerns.
C: A monoamine oxidase inhibitor (MAOI) is less commonly used due to dietary restrictions and potential side effects, and it is not the first-line treatment for PMS, making it an impractical choice for this patient.
SSRIs are often prescribed for PMS due to their effectiveness in reducing mood-related symptoms such as irritability and depression, which can significantly disrupt quality of life. They also help with physical symptoms by influencing neurotransmitter levels, making them a suitable option for this patient.
A: An opioid analgesic is not appropriate for PMS management, as it primarily addresses pain and may lead to dependency without targeting the underlying hormonal or emotional issues associated with the condition.
B: A calcium channel blocker does not address the core symptoms of PMS and is typically used for cardiovascular conditions, making it unsuitable for this patient's hormonal-related symptoms and quality of life concerns.
C: A monoamine oxidase inhibitor (MAOI) is less commonly used due to dietary restrictions and potential side effects, and it is not the first-line treatment for PMS, making it an impractical choice for this patient.